Arix Bioscience (ARIX)
ARIX Share PerformanceMore
|52 week high||218.00 17/02/17|
|52 week low||167.50 16/08/17|
|52 week change||0.00 (0.00%)|
|4 week volume||362,485 16/11/17|
Latest News« previous» nextMore
04/12/2017 - 07:32 StockMarketWire
Arix Bioscience has led an oversubscribed $30 million series F financing round for Atox Bio. Atox Bio is a late stage clinica...
04/12/2017 - 07:00 RNS
RNS Number: 2209Y Arix Bioscience Plc 04 December 2017 Arix Bioscience leads $30 million financing for Atox Bio Funding to advance Reltecimod into a Phase 2 clinical study for acute kidney injury, building upon Atox Bio's on-going Phase 3 clinical development in necrotising soft tissue infections Arix achieves target of 12 Group Businesses by the end of 2017, suc...
10/11/2017 - 09:11 StockMarketWire
Arix Bioscience non-executive director Sir John Banham is retiring from the board. The company said: 'Sir John, who is 76...
10/11/2017 - 09:00 RNS
RNS Number: 1565W Arix Bioscience Plc 10 November 2017 Sir John Banham retires from Board of Directors of Arix Bioscience plc LONDON, 10 November 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience" or "the Company"), a global healthcare and life science company supporting medical innovation, today announces that Sir John Banham is retiring fro...
01/11/2017 - 07:00 RNS
RNS Number: 1740V Arix Bioscience Plc 01 November 2017 Arix Bioscience to present at two investor conferences in November LONDON, 1 November 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience") a global healthcare and life science company supporting medical innovation, will present at two investor conferences in November: Stifel 2017 Healthcare Co...
18/10/2017 - 12:31 RNS
RNS Number: 9605T Arix Bioscience Plc 18 October 2017 Arix Bioscience notes Harpoon Therapeutics' immuno-oncology collaboration with AbbVie LONDON, 18 October 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience"), a global healthcare and life science company supporting medical innovation, is pleased to note that Harpoon Therapeutics ("Harpoon"), an...
17/10/2017 - 08:18 StockMarketWire
Arix Bioscience has appointed Giles Kerr as a non-executive director and chairman of the board's audit committee. Kerr h...
17/10/2017 - 06:10 RNS
RNS Number: 7531T BTG PLC 17 October 2017 BTG plc 17 October 2017 Director Declaration BTG plc announces today that Mr Giles Kerr, Non-executive Director of the Company, has been appointed as a Non-executive Director and Audit Committee Chair of Arix Bioscience plc with effect from 17 October 2017. This announcement is made pursuant to Listing Rule...
|Dividend yield||0 %|
Latest discussion posts More
“ Blimey, what's going on? Some negative news out there? IPO oversubscribed and some major holdings - it should be heading the other way. JC ”▼
“Been a bit of a dog so far”▼
“I could not make sense as to what this company is about. Is it similar to Shire which funds R&D through other Biotechs, but it does not have its owns labs?”▼
Codes & Symbols
|Symbols||ARIX, LSE:ARIX, ARIX.L, ARIX:LN, LON:ARIX, XLON:ARIX|
Join interactive investor
- £22.50 fixed quarterly charge includes £22.50 in trading credits
- £10 per trade or £6 for frequent traders
- No % platform fees
- £1 per trade for regular investment or dividend reinvestment